Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer

被引：0
|
作者：
Nakao, Masayuki [1 ]
Ichinose, Junji [1 ]
Matsuura, Yosuke [1 ]
Okumura, Sakae [1 ]
Mun, Mingyon [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Surg Oncol, Tokyo, Japan
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 18期
关键词：
D O I：
10.21037/atm.2020.04.34
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
    Sos, Martin L.
    Koker, Miriam
    Weir, Barbara A.
    Heynck, Stefanie
    Rabinovsky, Rosalia
    Zander, Thomas
    Seeger, Jens M.
    Weiss, Jonathan
    Fischer, Florian
    Frommolt, Peter
    Michel, Kathrin
    Peifer, Martin
    Mermel, Craig
    Girard, Luc
    Peyton, Michael
    Gazdar, Adi F.
    Minna, John D.
    Garraway, Levi A.
    Kashkar, Hamid
    Pao, William
    Meyerson, Matthew
    Thomas, Roman K.
    CANCER RESEARCH, 2009, 69 (08) : 3256 - 3261
  • [42] Molecular dynamics prediction of the mechanism of acquired resistance to EGFR inhibitors in EGFR-mutant lung cancer
    Lee, Youngjoo
    Choi, Yu-Ra
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
    Syrigos, Konstantinos
    Kotteas, Ilias
    Paraskeva, Maria
    Gkiozos, Ioannis
    Boura, Paraskevi
    Tsagouli, Sofia
    Grapsa, Dimitra
    Charpidou, Andriani
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [44] A protein synthesis switch underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors
    Song, Kyung-A
    Lochmann, Timothy L.
    Patel, Neha U.
    Ham, Jungoh
    Windle, Brad E.
    Harada, Hisashi
    Leverson, Joel D.
    Souers, Andrew J.
    Hata, Aaron N.
    Ebi, Hiromichi
    Faber, Anthony C.
    CLINICAL CANCER RESEARCH, 2018, 24 (17)
  • [45] Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
    Piper-Vallillo, Andrew J.
    Sequist, Lecia V.
    JACC: CARDIOONCOLOGY, 2019, 1 (02): : 179 - 181
  • [46] CO-OCCURRING ALTERATIONS AFFECT OUTCOMES IN EGFR-MUTANT LUNG CANCER
    不详
    CANCER DISCOVERY, 2018, 8 (01) : 9 - 9
  • [47] EGFR-mutant lung cancer: what's new with respect to activity and resistance?
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2018, 11 : S73 - S77
  • [48] Impact of Ethnicity on Incidence of Brain Metastasis in Patients with EGFR-Mutant Lung Cancer
    Zhang, Jiexia
    Wen, Huiyu
    Cai, Di
    La, Hahn
    Gandara, David R.
    He, Jianxin
    Qi, Lihong
    Li, Tianhong
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S591 - S591
  • [49] Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer
    Li, Wendong
    Rotter-Maskowitz, Aviva
    Zhang, Keqiang
    Massarelli, Erminia
    Potempa, Jan
    Straussman, Ravid
    Raz, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?
    Aggarwal, Charu
    Gyawali, Bishal
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3103 - +
12345